Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 3 trial of once-weekly subcutaneous zenagamtide in adults with overweight or obesity and untreated obstructive sleep apnoea
2024-520442-36-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and obstructive sleep apnea hypopnea syndrome (OSAHS) comparing Zenagamtide once weekly with Placebo once weekly (2 arms). Primary endpoints: Relative change in body weight and Change in apnoea-hypopnoea index. Planned start Apr 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
obesityOverweightobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2024-520442-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520442-36-00.